Tags

Type your tag names separated by a space and hit enter

Hormones and hormone antagonists: mechanisms of action in carcinogenesis of endometrial and breast cancer.
Horm Metab Res. 2001 Aug; 33(8):451-7.HM

Abstract

Proliferation of breast and endometrial cells is under the control of ovarian steroid hormones (SHs) such as oestrogen and progesterone. They mediate diverse physiological functions via interaction with nuclear-localised steroid hormone receptors (HRs). The SH receptor complex modifies the expression of SH-regulated genes by binding to conserved binding sites in their promoter region or through cross-talk with other transcription factors. In non-malignant tissues, HRs are in balance with other factors regulating proliferation, differentiation and apoptosis. While dysfunction of the regulatory mechanisms is a part of malignant transformation, functional SH receptors can promote growth of SH-responsive tumours. Therefore, anti-hormones that block the interaction of steroid hormones with the SH receptor are useful tools for the treatment of SH-responsive carcinomas. However, a portion of ER-positive breast cancers and most endometrial cancers do not respond to anti-oestrogens and continued treatment results in hormone resistance, mostly without loss of the ER. This review focuses on the mechanisms of action of hormones and anti-hormones in breast and endometrial carcinomas.

Authors+Show Affiliations

University Hospital Düsseldorf, Department of Obstetrics and Gynaecology, Düsseldorf, Germany.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

11544557

Citation

Flötotto, T, et al. "Hormones and Hormone Antagonists: Mechanisms of Action in Carcinogenesis of Endometrial and Breast Cancer." Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme, vol. 33, no. 8, 2001, pp. 451-7.
Flötotto T, Djahansouzi S, Gläser M, et al. Hormones and hormone antagonists: mechanisms of action in carcinogenesis of endometrial and breast cancer. Horm Metab Res. 2001;33(8):451-7.
Flötotto, T., Djahansouzi, S., Gläser, M., Hanstein, B., Niederacher, D., Brumm, C., & Beckmann, M. W. (2001). Hormones and hormone antagonists: mechanisms of action in carcinogenesis of endometrial and breast cancer. Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme, 33(8), 451-7.
Flötotto T, et al. Hormones and Hormone Antagonists: Mechanisms of Action in Carcinogenesis of Endometrial and Breast Cancer. Horm Metab Res. 2001;33(8):451-7. PubMed PMID: 11544557.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Hormones and hormone antagonists: mechanisms of action in carcinogenesis of endometrial and breast cancer. AU - Flötotto,T, AU - Djahansouzi,S, AU - Gläser,M, AU - Hanstein,B, AU - Niederacher,D, AU - Brumm,C, AU - Beckmann,M W, PY - 2001/9/7/pubmed PY - 2002/1/5/medline PY - 2001/9/7/entrez SP - 451 EP - 7 JF - Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme JO - Horm Metab Res VL - 33 IS - 8 N2 - Proliferation of breast and endometrial cells is under the control of ovarian steroid hormones (SHs) such as oestrogen and progesterone. They mediate diverse physiological functions via interaction with nuclear-localised steroid hormone receptors (HRs). The SH receptor complex modifies the expression of SH-regulated genes by binding to conserved binding sites in their promoter region or through cross-talk with other transcription factors. In non-malignant tissues, HRs are in balance with other factors regulating proliferation, differentiation and apoptosis. While dysfunction of the regulatory mechanisms is a part of malignant transformation, functional SH receptors can promote growth of SH-responsive tumours. Therefore, anti-hormones that block the interaction of steroid hormones with the SH receptor are useful tools for the treatment of SH-responsive carcinomas. However, a portion of ER-positive breast cancers and most endometrial cancers do not respond to anti-oestrogens and continued treatment results in hormone resistance, mostly without loss of the ER. This review focuses on the mechanisms of action of hormones and anti-hormones in breast and endometrial carcinomas. SN - 0018-5043 UR - https://www.unboundmedicine.com/medline/citation/11544557/Hormones_and_hormone_antagonists:_mechanisms_of_action_in_carcinogenesis_of_endometrial_and_breast_cancer_ L2 - https://www.thieme-connect.com/DOI/DOI?10.1055/s-2001-16936 DB - PRIME DP - Unbound Medicine ER -